---
figid: PMC4094296__nihms352079f3
figtitle: Pathogenetic Importance and Therapeutic Implications of NFKB in Lymphoid
  Malignancies
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Danio rerio
pmcid: PMC4094296
filename: nihms352079f3.jpg
figlink: /pmc/articles/PMC4094296/figure/F3/
number: F3
caption: 'The pathogenesis of ABC DLBCL involves constitutive activation of BCR, MyD88
  and IL-6/IL-10 signaling pathway, promoting cell survival through NF-κB, STAT3 and
  PI3K signaling pathways. Signaling in these pathways is induced or accentuated by
  recurrent mutations in ABC DLBCL that affect CD79B, MyD88, CARD11 and A20 (denoted
  with and asterisk). Therapeutic targets in ABC DLBCL and exemplar small molecule
  inhibitors include: 1. Src-family kinase (Dasatinib) (); 2. SYK (fostamatinib/R406)
  (, ); 3. PI3Kδ (CAL-101) (, , ); 4. mTOR (rapamycin) (); 5. BTK (PCI-32765, Dasatinib)
  (); 6. PKCβ (Sotrastaurin) (, ); 7. MALT1 (, ); 8. IKKβ (MLN120B) (, , ); 9. HSP90
  (geldanomycin) (, ); 10. IRAK4 (); 11. NEDD8-activating enzyme (NAE) (MLN4924);
  JAK1 (AZD1480) (, ); 12. Proteasome (bortezomib) ().'
papertitle: Pathogenetic Importance and Therapeutic Implications of NF-κB in Lymphoid
  Malignancies.
reftext: Kian-Huat Lim, et al. Immunol Rev. ;246(1):359-378.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9585494
figid_alias: PMC4094296__F3
figtype: Figure
redirect_from: /figures/PMC4094296__F3
ndex: 58fe287e-dec0-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4094296__nihms352079f3.html
  '@type': Dataset
  description: 'The pathogenesis of ABC DLBCL involves constitutive activation of
    BCR, MyD88 and IL-6/IL-10 signaling pathway, promoting cell survival through NF-κB,
    STAT3 and PI3K signaling pathways. Signaling in these pathways is induced or accentuated
    by recurrent mutations in ABC DLBCL that affect CD79B, MyD88, CARD11 and A20 (denoted
    with and asterisk). Therapeutic targets in ABC DLBCL and exemplar small molecule
    inhibitors include: 1. Src-family kinase (Dasatinib) (); 2. SYK (fostamatinib/R406)
    (, ); 3. PI3Kδ (CAL-101) (, , ); 4. mTOR (rapamycin) (); 5. BTK (PCI-32765, Dasatinib)
    (); 6. PKCβ (Sotrastaurin) (, ); 7. MALT1 (, ); 8. IKKβ (MLN120B) (, , ); 9. HSP90
    (geldanomycin) (, ); 10. IRAK4 (); 11. NEDD8-activating enzyme (NAE) (MLN4924);
    JAK1 (AZD1480) (, ); 12. Proteasome (bortezomib) ().'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BCR
  - RN7SL263P
  - MYD88
  - IL6
  - IL10
  - SYK
  - IRAK4
  - JAK1
  - IRAK1
  - BTK
  - STAT3
  - PRKCB
  - CARD11
  - MALT1
  - TNFAIP3
  - IGKV1-27
  - BCL10
  - IKBKG
  - AKT1
  - AKT2
  - AKT3
  - HSP90B2P
  - MTOR
  - RELA
  - SYT1
  - GORASP1
  - WNK1
  - CD40
  - ARHGEF7
  - ASCC1
  - H3P40
  - NFKB1
  - bcr
  - myd88
  - il6
  - il10
  - syk
  - irak4
  - jak1
  - irak1
  - btk
  - stat3
  - prkcbb
  - card11
  - malt1
  - malt2
  - bcl10
  - serpinh1b
  - mtor
  - rela
  - nfkb1
---
